Bayer Aktiengesellschaft (BAYRY) Expected to Announce Earnings on Tuesday

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) will likely be issuing its resultson Tuesday, May 12th. Analysts expect the company to announce earnings of $0.64 per share and revenue of $15.7720 billion for the quarter. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, hitting analysts’ consensus estimates of $0.18. The company had revenue of $13.24 billion for the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft had a positive return on equity of 15.93% and a negative net margin of 8.51%. On average, analysts expect Bayer Aktiengesellschaft to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bayer Aktiengesellschaft Price Performance

Bayer Aktiengesellschaft stock traded up $0.22 on Tuesday, reaching $11.05. The company’s stock had a trading volume of 936,144 shares, compared to its average volume of 1,239,743. Bayer Aktiengesellschaft has a twelve month low of $6.20 and a twelve month high of $14.85. The business’s fifty day moving average price is $11.46 and its 200 day moving average price is $10.80. The company has a market cap of $43.41 billion, a price-to-earnings ratio of -9.95 and a beta of 0.62. The company has a debt-to-equity ratio of 1.22, a quick ratio of 0.63 and a current ratio of 1.01.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BAYRY shares. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Finally, Zacks Research lowered Bayer Aktiengesellschaft from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 24th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Bayer Aktiengesellschaft has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.